Shenqi Pharmaceutical's Furunai Zhu monoclonal antibody injection has been approved for domestic market.

On June 9th, Shenqi Pharmaceuticals announced that Ajovy has been officially approved by the National Medical Products Administration for the preventive treatment of migraines in adults. Ajovy is a monoclonal antibody that targets the calcitonin gene-related peptide. Among the currently available CGRP monoclonal antibody drugs, Ajovy is the only subcutaneous injection drug that offers the option of either "once a month" or "once every three months" dosing regimens.